Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals Inc demonstrates a strong positive outlook based on several key developments, including the expected long-term market exclusivity for milsaperidone, which extends to 2044, supporting sustained revenue growth from its established products. The recent approval and positive clinical results for tradipitant in treating nausea and vomiting associated with GLP-1 receptor agonists indicate significant potential for enhanced compliance and demand in the growing obesity treatment market. Furthermore, the favorable safety profile observed in the NEREUS program for tradipitant underscores the company's commitment to innovative therapies that meet high unmet medical needs, positioning Vanda favorably for future growth and market expansion.

Bears say

Vanda Pharmaceuticals faces several substantial risks that contribute to a negative financial outlook, including slower-than-anticipated sales traction for its key products, Fanapt and Ponvory, and the threat of accelerating generic erosion, particularly impacting Fanapt and Hetlioz. Furthermore, the company is susceptible to negative pricing developments, especially regarding Medicare reimbursement, which may further hinder revenue generation. Additionally, potential regulatory setbacks with late-stage pipeline candidates and adverse clinical readouts raise concerns about the company's ability to achieve growth and maintain shareholder value in the medium to long term.

Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 5 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.